Showing 891-900 of 1603 results for "".
- American Acne and Rosacea Society (AARS) Now Accepting Research Grant Award Applicationshttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-aars-is-now-accepting-applications-for-research-grant-awards/2462440/The American Acne and Rosacea Society (AARS) has announced the commencement of its grant application cycle for AARS Clinical Research Awards ($10K) and the prestigious AARS Research Scholar Award ($75K). According to a press release, the AARS offers its Clinical Research Awards for the a
- Shaperon Enrolls First Patient in Phase 2 Clinical Trial for Atopic Dermatitis Therapy 'Nugel'https://practicaldermatology.com/news/shaperon-enrolls-first-patient-in-phase-2-clinical-trial-for-atopic-dermatitis-therapy-nugel/2462439/Shaperon announced the enrollment of the first patient in the phase 2 clinical trial for atopic dermatitis treatment candidate Nugel. The trial will evaluate the efficacy of Nugel in improving the Eczema Area Severity Index (EASI) across a cohort of 210 patients with mild to moderate atop
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- Povorcitinib Shows Efficacy and Safety in Patients with Prurigo Nodularishttps://practicaldermatology.com/news/study-povorcitinib-safe-and-effective-for-prurigo-nodularis/2462426/The oral JAK1 inhibitor povorcitinib was shown to improve itch in prurigo nodularis, and also met its primary endpoints, according to new phase 2 data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the study enrolled 146 participants and
- LITE: Home-based Narrow Band UVB Phototherapy for Psoriasis Non-Inferior to Office-based Treatmenthttps://practicaldermatology.com/news/lite-home-based-narrow-band-uv-b-phototherapy-for-psoriasis-noninferior-to-office-based-treatment/2462425/Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home
- FRONTIER-2: Novel Oral Peptide Maintains Safety, Efficacy Out to 1 Yearhttps://practicaldermatology.com/news/frontier-2-novel-il-23-targting-oral-peptide-maintains-safety-efficacy-out-to-1-year/2462424/A targeted oral peptide targeting interleukin-23 (IL-23) was associated with high rates of clearance and consistent safety through 1 year of treatment in adults with moderate-to-severe plaque psoriasis, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- ADORING Trials: Tapinarof Cream, 1% Effective in Patients with Skin of Colorhttps://practicaldermatology.com/news/adoring-trials-tapinarof-effective-in-patients-with-skin-of-color/2462266/In a patient population with diverse skin tones, tapinarof cream, 1% (VTAMA®, Dermavant) was shown to have significant efficacy in both adults and children as young as 2 years of age with atopic dermatitis (AD), according to new results presented at the 2024 American Academy of Dermatology Annual